Pharmacom Labs Jaros - Tirzepatide Compound Peptide - Mounjaro Vial 15mg

Tirzepatide is a new-generation medication for weight loss, treatment of obesity, and treatment of diabetes mellitus.
It is a dual receptor agonist (GIP and GLP-1), unlike Ozempic, which is an agonist of only GLP-1.
The drug was officially approved by the FDA (USA) in 2022 for the treatment of obesity and type 2 diabetes. In Europe, it was approved in 2023.

A double strike against obesity:

Activation of GLP-1 receptors
suppresses glucagon secretion, which raises blood sugar levels,
slows gastric emptying, which leads to a slower entry of glucose into the bloodstream,
affects the satiety centers in the hypothalamus, reducing appetite and increasing the feeling of fullness.
This promotes weight loss.

Activation of GIP receptors (the key difference from GLP-1–only analogues):
enhances the effects of GLP-1 and improves the metabolism of fat cells (adipocytes).

Synergistic effect:
The combination of two mechanisms in a single molecule provides a more powerful effect on blood glucose levels and body weight compared with drugs of the GLP-1–only class (for example, semaglutide, liraglutide).

✅ Supports feelings of fullness and satiety after meals. paired with proper diet and exercise. search1

✅ Supports healthy blood glucose regulation and metabolic wellness. 0search7

✅ Once-weekly administration for convenience and consistency. abolic & Weight Management Support.

Disclaimer

This product is intended strictly for laboratory research purposes only. It is not a medicine and has not been evaluated or approved by the South African Health Products Regulatory Authority (SAHPRA) for human or animal use.

Not for human consumption or medical use. Products sold on this website are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, the customer confirms they are qualified to handle and use this product in accordance with applicable laws and regulations.